Setting our AdipoSIGHTS on Stem Cells in Pharmacogenomics

Holmes, 2016, Diabetes: Genetic variation underpins metformin response, Nat. Rev. Endocrinol., 12, 626 Hu, 2019, Patient adipose stem cell-derived adipocytes reveal genetic variation that individualizes anti-diabetic drug response, Cell Stem Cell, 24, 299, 10.1016/j.stem.2018.11.018 Meriden, 2004, Progress with thiazolidinediones in the management of type 2 diabetes mellitus, Clin. Ther., 26, 177, 10.1016/S0149-2918(04)90017-3 Roden, 2006, Pharmacogenomics: challenges and opportunities, Ann. Intern. Med., 145, 749, 10.7326/0003-4819-145-10-200611210-00007 Rosenblit, 2016, Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?, Cardiovasc. Diabetol., 15, 95, 10.1186/s12933-016-0412-7 Segrè, 2015, Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk, Diabetes, 64, 1470, 10.2337/db14-0703 Soccio, 2014, Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes, Cell Metab., 20, 573, 10.1016/j.cmet.2014.08.005 Ye, 2004, Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin, Diabetologia, 47, 1306, 10.1007/s00125-004-1436-1 Yki-Järvinen, 2004, Thiazolidinediones, N. Engl. J. Med., 351, 1106, 10.1056/NEJMra041001